Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05158140 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 850
- Enrollment target
NCT05158140 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 850 participants.
The verdict
NCT05158140, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 850 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive pneumococcal disease.
Interventions
- BIOLOGICAL mRNA-1273
- BIOLOGICAL V114
- BIOLOGICAL V110
- BIOLOGICAL Placebo for V110
- BIOLOGICAL Placebo for V114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05158140
The ClinicalTrials.gov registry entry for NCT05158140 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mRNA-1273 is the first listed.
NCT05158140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05158140 about?
NCT05158140 is a clinical study titled "Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)". The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2)...
What is the current status of trial NCT05158140?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2022-01-12. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT05158140?
The interventions under investigation include: mRNA-1273 (BIOLOGICAL), V114 (BIOLOGICAL), V110 (BIOLOGICAL), Placebo for V110 (BIOLOGICAL), Placebo for V114 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05158140?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.